Articles, Publications, Commentaries, Reports and White Papers 


Understanding that some of the ideas, concepts, processes and technologies described herein may

be unfamiliar to various readers we provide the following support documents and resources.

(Click to Download)


This document describes the HERO Voluntary Healthcare Research Benefit which enables Plan Participants to access leading-edge care and advance medical research.

This article details why the scientific research that proves the efficacy of precision medicine provides no evidence re: cost-effectiveness, ROI, value, outcomes, etc.



This document describes our perspective on the changing healthcare environment and why a new research approach is required to satisfy more advanced payor needs.



This document provides a detailed overview of the healthcare industry from a layperson's perspective and how we intend to conduct translational research.



This document provides an overview of precision medicine, pharmacogenomics (PGx) and the value and use of genetics/genomics in medical treatment.



This article details how a pharmaceutical company changed its personnel policies and health plan provisions to encourage employee participation in clinical trials.



This article describes how researchers and payers are collaborating to design research studies that satisfy the needs of payers for evidence to warrant coverage.



The report summarizes research conducted to determine why, when and to what extent patients will share their health data with researchers and their health plan.




This SHYFT report is on Using Real-World Evidence to Optimize Clinical Trials(Improving Trial Design, Patient Recruitment, and Data Analysis)





This CBT Advisors white paper provides insight for investors re: translational research as a way to produce clinical, commercial and financial outcomes. 



The document below is the draft text of a bipartisan, senate-proposed PCORI reauthorization bill that we spported and helped lobby on behalf of.



This document is the first reported official version of H.R. 1865, the PCORI Reauthorization Act of 2019 direct via the Congressional staffers who authored it.



The document below is the draft text of a bipartisan, Senate-proposed PCORI reauthorization bill that we supported and helped lobby on behalf of.



This document is the first reported official version of H.R. 1865, the PCORI Reauthorization Act of 2019 direct via the Congressional staffers who authored it.